Hint mode is switched on Switch off

Candel Therapeutics, ordinary share
CADL, US1374041093

Add a stock to WL
Choose all Reset all
Candel Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies.
  • Issuer
  • Full borrower / issuer name
    Candel Therapeutics Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    CADL
  • Placement
    27.07.2021
  • Lock up period
    180
  • Number of papers
    9,000,000
  • Volume of raised funds
    72 mln USD
  • Placement share
    32.38%
  • Final placement price
    8 USD
  • Price change since placement date
    -100%
  • By capitalization
    222.39 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    CADL
  • Placement
    13.12.2024
  • Lock up period
    180
  • Number of papers
    10,000,001
  • Volume of raised funds
    60 mln USD
  • Placement share
    23.74%
  • Final placement price
    6 USD
  • Price change since placement date
    73.33%
  • By capitalization
    252.75 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    CADL
  • Placement
    20.02.2026
  • Lock up period
    180
  • Number of papers
    18,348,624
  • Volume of raised funds
    100 mln USD
  • Placement share
    25.05%
  • Final placement price
    5.45 USD
  • Price change since placement date
    90.83%
  • By capitalization
    399.18 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
II q eng
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

12/06/2026 Candel Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
19/02/2026 Candel Therapeutics: Entry Into A Material Definitive Agreement, Results Of Operations And Financial Condition, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
14/10/2025 Candel Therapeutics: Entry Into A Material Definitive Agreement, Results Of Operations And Financial Condition, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
18/08/2025 Candel Therapeutics: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
23/06/2025 Candel Therapeutics: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.